This will be nowhere near 10x after Phase 1. Phase 1 is to see how safe this is in healthy patients. It has nothing to do with how effective this will be in stroke patients. Maybe after Phase 2 it might take off but that's after success, a few years and more dilution. Would like to see more diversification in their pipeline instead of just the one drug.
ARGENICA THERAPEUTICS LIMITED IPO Analysis, page-14
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
-0.015(1.94%) |
Mkt cap ! $93.34M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 80.0¢ | 76.0¢ | $215.8K | 271.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 666 | 75.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 77.0¢ | 12418 | 4 |
View Market Depth
| Last trade - 13.30pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
76.5¢ |
Change
-0.015 ( 2.20 %) |
||||
| Open | High | Low | Volume | ||
| 80.0¢ | 80.0¢ | 76.0¢ | 47589 | ||
| Last updated 13.38pm 30/05/2024 ? | |||||
| AGN (ASX) Chart |